FLYSYN by VERAXA Biotech for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

Adap­ti­m­mune Ther­a­peu­tics and Gala­pa­gos have formed an al­liance to man­u­fac­ture a clin­i­cal-stage sol­id can­cer as­set in a de­cen­tral­ized way. At the cen­ter of the deal

The FDA approved colchicine (Lodoco) for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with

T cells have proven highly effective at attacking cancer cells. Credit: Sebastian Kaulitzki via Shutterstock. The progress of advanced therapeutics in recent years, especially in